Michael R. Schlabach

Q Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index7.9kcitations85works2.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(35), PARP inhibition in cancer therapy(16), Advanced biosensing and bioanalysis techniques(9), RNA modifications and cancer(9), DNA Repair Mechanisms(8)

Publications85 total

Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8 <sup>+</sup> T cell fate to enhance anti-tumor functionality
2026Open Access
Data from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S8 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S4 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Supplementary Table 3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Supplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S7 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S5 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S6 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S9 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Figure S3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
Supplementary Table 2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
2024Open Access
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Cancer Research·2024· 34 citedOpen Access
Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens
Journal of Clinical Investigation·2023· 30 citedOpen Access
Rational design of a SOCS1-edited tumor infiltrating lymphocyte therapy for solid tumors using CRISPR/Cas9 screens
2023· 4 citedOpen Access
Abstract 2771: KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death
Cancer Research·2023· 1 cited
Supplementary Table S5 from CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions
2023Open Access
Supplementary Table S3 from CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Frank Stegmeier(26), Stephen J. Elledge(15), David A. Ruddy(14), Sol Shenker(11), Louise Cadzow(10), William R. Sellers(9), Hugh Gannon(9), Nicholas Keen(8), Kristine Yu(7), Mamie Z. Li(7), Daniel P. Rakiec(7), Anthony C. Liang(7), Qikai Xu(7), Elsa Krall(7), Ji Luo(6), Antoine de Weck(6), Éric Billy(6), Francesco Hofmann(6), Tobias Schmelzle(6), Nicole L. Solimini(6)